Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin B6 as adjunctive therapy for positive and cognitive symptoms in chronic schizophrenia and schizoaffective disorder
IRCT20251015067645N1Phase 4Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of pyridoxine in schizophrenia and schizoaffective disorder (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Change in positive symptoms of schizophrenia and Change in cognitive symptoms. Started Dec 2025; status: completed.
02
Drugs
pyridoxine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on IRCT20251015067645N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251015067645N1.